Your search for tofacitinib returned 5 results

Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.

A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.

Although found to increase the risk of infectious complications, janus kinase (JAK) inhibitors effectively induce clinical remission in patients with Crohn disease (CD) and clinical and endoscopic remission in patients with ulcerative colitis (UC), according to results of a recently published systematic review and meta-analysis.

Fleischmann, R et al. “Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.” DOI: http://dx.doi.org/10.1016/S0140-6736(17)31618-5

Sandborn, WJ et al. “Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.” DOI: 10.1056/NEJMoa1606910